AstraZeneca shares rise as China probe update reassures
AstraZeneca on Thursday said it could face a fine of up to $4.5 million in China over suspected unpaid import taxes, raising investor hopes that the impact of several probes in the country could be minor and leading its shares to rise about 5%.
AstraZeneca sales jump despite troubles in China
Sales in China fell 3 per cent during the quarter. AstraZeneca said this was mainly because the winter had been mild, causing a drop in sales of respiratory drugs used to treat viral infections. It also cited annual budget caps at Chinese hospitals.
AstraZeneca’s planned vaccine hub for Liverpool is off the table - business editor Karl Matchett and Whitehall editor Kate ...
Lord Storey says he fears Merseyside was "not a high priority" on the government's growth agenda.
The pharmaceuticals major was boosted by high demand for its key drugs that offset a slight sales drop in China.
The boss of AstraZeneca Plc said he does not believe the UK is the worst place to invest, striking a conciliatory tone just ...
Buying Alexion remains a “fantastic acquisition” for AstraZeneca, the Big Pharma’s CEO has said, even as the company takes a ...
In a report released today, Emmanuel Papadakis from Deutsche Bank maintained a Hold rating on AstraZeneca (AZN – Research Report), with a ...
Pascal Soriot, chief executive of AstraZeneca, denied any rift with the Government over the decision, which it revealed ...
A fresh earnings release was the news development powering AstraZeneca's (NASDAQ: AZN) share price higher on Thursday.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback